Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ZNF628 divergent transcript (ZNF628-DT) is a long non-coding RNA located near the ZNF628 gene on chromosome 19. Divergent transcripts, as defined by the HUGO Gene Nomenclature Committee (HGNC), are lncRNA genes found within several hundred nucleotides upstream or downstream of protein-coding genes, transcribed in the opposite orientation[5]. ZNF628-DT does not code for a protein, and there is no evidence that it is a therapeutic target, marker, or implicated in disease processes[1][2][5]. Divergent transcripts are often produced as a byproduct of active gene transcription, sometimes involved in regulatory or evolutionary processes, but specific functional roles for ZNF628-DT have not been reported[4][5]. Notes on correctness: - ZNF628-DT is not itself a protein, receptor, or enzymatic target. - The entry likely represents an annotation or transcript of unclear or uncharacterized functional relevance, rather than a molecule of direct therapeutic interest. - If a therapeutic target was intended, a confusion between ZNF628 (the protein-coding gene) and ZNF628-DT (the non-coding RNA) may have occurred[3][6]. - There are no drugs, biomarkers, or disease associations currently recognized for ZNF628-DT. If you require information on the protein-coding gene ZNF628 itself (zinc finger protein 628), that gene is a DNA-binding transcription factor, but ZNF628-DT is not the same entity[3][6].
Not applicable
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ZNF628 divergent transcript (ZNF628-DT).